Payment overview · 2025
General Payments
$91.57
5 reported records · 3 companies
Healthcare provider profile · identity verified
Lawrence D. Loehle, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LOUISVILLE, KY · NPI 1477517241
Verified facts
What the public records show
CMS Open Payments records show Lawrence D. Loehle, M.D. received $91.57 in general payments during 2025 across 5 reported records.
ABBVIE INC. accounted for 60.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.44 | 60.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.16 | 22.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.97 | 17.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $91.57 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $41.63 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $41.63 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
79 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
100 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 656 | 193 |
| Amlodipine Besylate | Amlodipine Besylate | 609 | 188 |
| Losartan Potassium | Losartan Potassium | 384 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 374 | 106 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 368 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 345 | 98 |
| Omeprazole | Omeprazole | 291 | 87 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 269 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 241 | 73 |
| Simvastatin | Simvastatin | 239 | 71 |
| Gabapentin | Gabapentin | 225 | 72 |
| Alprazolam | Alprazolam | 212 | 42 |
| Irbesartan | Irbesartan | 183 | 53 |
| Metformin Hcl Er | Metformin Hcl | 166 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 57 |
| Valsartan | Valsartan | 154 | 45 |
| Eliquis | Apixaban | 146 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 146 | 43 |
| Meloxicam | Meloxicam | 146 | 36 |
| Lisinopril | Lisinopril | 144 | 44 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 129 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 128 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 123 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 122 | 45 |
| Xarelto | Rivaroxaban | 112 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 31 |
| Jardiance | Empagliflozin | 103 | 29 |
| Farxiga | Dapagliflozin Propanediol | 100 | 26 |
| Allopurinol | Allopurinol | 97 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 94 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 35 |
| Lorazepam | Lorazepam | 86 | 23 |
| Prednisone | Prednisone | 81 | 33 |
| Trazodone Hcl | Trazodone Hcl | 80 | 30 |
| Synthroid | Levothyroxine Sodium | 79 | 23 |
| Estradiol | Estradiol | 77 | 23 |
| Furosemide | Furosemide | 77 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 77 | 22 |
| Sertraline Hcl | Sertraline Hcl | 77 | 30 |
| Carvedilol | Carvedilol | 76 | 27 |
| Spironolactone | Spironolactone | 75 | 26 |
| Finasteride | Finasteride | 74 | 22 |
| Montelukast Sodium | Montelukast Sodium | 74 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 68 | 20 |
| Ezetimibe | Ezetimibe | 66 | 20 |
| Bupropion Xl | Bupropion Hcl | 65 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 63 | 44 |
| Ozempic | Semaglutide | 61 | 11 |
| Tramadol Hcl | Tramadol Hcl | 61 | 17 |
| Atenolol | Atenolol | 60 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 19 |
| Mounjaro | Tirzepatide | 56 | suppressed |
| Lansoprazole | Lansoprazole | 55 | 17 |
| Clonazepam | Clonazepam | 54 | suppressed |
| Indapamide | Indapamide | 54 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 24 |
| Donepezil Hcl | Donepezil Hcl | 49 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 14 |
| Metformin Hcl | Metformin Hcl | 45 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | 11 |
| Famotidine | Famotidine | 43 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 12 |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 43 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 12 |
| Cefdinir | Cefdinir | 35 | 32 |
| Testosterone | Testosterone | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 15 |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Invokana | Canagliflozin | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 15 |
| Olanzapine | Olanzapine | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 17 |
| Pregabalin | Pregabalin | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Potassium Chloride | Potassium Chloride | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 16 |
| Cephalexin | Cephalexin | 19 | 16 |
| Felodipine Er | Felodipine | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Baclofen | Baclofen | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $91.57 · 5 records | ABBVIE INC. | AIRSUPRA, OTEZLA, QULIPTA, REPATHA, UBRELVY, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error